Nvwm LLC Has $30,000 Holdings in Novo Nordisk A/S (NYSE:NVO)

Nvwm LLC decreased its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 97.0% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 348 shares of the company’s stock after selling 11,447 shares during the quarter. Nvwm LLC’s holdings in Novo Nordisk A/S were worth $30,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of NVO. AQR Capital Management LLC boosted its holdings in Novo Nordisk A/S by 110.5% in the second quarter. AQR Capital Management LLC now owns 17,164 shares of the company’s stock worth $2,450,000 after acquiring an additional 9,012 shares in the last quarter. Mather Group LLC. raised its position in shares of Novo Nordisk A/S by 4.3% during the third quarter. Mather Group LLC. now owns 5,835 shares of the company’s stock worth $695,000 after purchasing an additional 243 shares during the period. Park Place Capital Corp bought a new position in shares of Novo Nordisk A/S in the 3rd quarter worth $119,000. Olistico Wealth LLC grew its position in Novo Nordisk A/S by 6.3% in the 3rd quarter. Olistico Wealth LLC now owns 7,731 shares of the company’s stock valued at $921,000 after purchasing an additional 460 shares during the period. Finally, Gratus Wealth Advisors LLC increased its stake in Novo Nordisk A/S by 69.0% during the 3rd quarter. Gratus Wealth Advisors LLC now owns 3,693 shares of the company’s stock valued at $435,000 after purchasing an additional 1,508 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock opened at $85.83 on Thursday. The stock has a market cap of $385.16 billion, a P/E ratio of 27.78, a P/E/G ratio of 0.93 and a beta of 0.45. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The company’s 50 day moving average price is $92.65 and its two-hundred day moving average price is $112.19. Novo Nordisk A/S has a 52 week low of $78.17 and a 52 week high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 86.32% and a net margin of 35.03%. On average, equities analysts predict that Novo Nordisk A/S will post 3.16 earnings per share for the current year.

Wall Street Analyst Weigh In

NVO has been the subject of a number of analyst reports. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. BMO Capital Markets lowered their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Finally, UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.